Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis
| Status: | Recruiting |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 95 |
| Updated: | 3/15/2019 |
| Start Date: | January 2015 |
| End Date: | December 2020 |
| Contact: | Robert S Feder, MD, MBA |
| Email: | r-feder@northwestern.edu |
| Phone: | 312-695-8150 |
A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Gancyclovir Gel (Zirgan) Versus 0.3% Hypromellose Gel (Genteal Gel; Placebo) for the Treatment of Herpes Zoster Keratitis
The purpose of this study is to evaluate the efficiency of topical gancyclovir 0.15% in the
treatment of herpes zoster keratitis. Half the patients will receive the study drug while the
other half of the patients will receive the placebo
treatment of herpes zoster keratitis. Half the patients will receive the study drug while the
other half of the patients will receive the placebo
Patients with herpes zoster keratitis will be enrolled in the study. All patients will
receive oral anti-viral medication as a standard-of-care therapy. The patients will be
randomized into two groups and given either the study drug or the placebo at the time of
enrollment. The patients will come for weekly visits during which slit lamp photograph of the
dendrite will be taken. At week 2, if the dendrite has not healed the drug will by unmasked
and rescue therapy will be given. the patients will be examined at week 1, 2, and 3 or until
resolution occurs.
receive oral anti-viral medication as a standard-of-care therapy. The patients will be
randomized into two groups and given either the study drug or the placebo at the time of
enrollment. The patients will come for weekly visits during which slit lamp photograph of the
dendrite will be taken. At week 2, if the dendrite has not healed the drug will by unmasked
and rescue therapy will be given. the patients will be examined at week 1, 2, and 3 or until
resolution occurs.
Inclusion Criteria:
- age 18 and above
- have not been on gancyclovir gel or any other form of topical antiviral therapy for
the past month
- able and willing to attend subsequent follow-up visits
Exclusion Criteria:
- Associated retinitis
- patients who are allergic to gancyclovir
- patients who will require systemic or intra-vitreal gancyclovir therapy
- patients who are pregnant or breastfeeding
We found this trial at
1
site
Click here to add this to my saved trials
